Mar 10, 2025 3:00pm EDT Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Feb 26, 2025 7:00am EST Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Feb 19, 2025 7:00am EST Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
Jan 10, 2025 7:00am EST Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Jan 02, 2025 7:00am EST Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Dec 23, 2024 7:00am EST Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Dec 17, 2024 7:00am EST Immunocore announces dosing of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Dec 11, 2024 7:00am EST EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
Dec 03, 2024 1:00am EST Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Nov 06, 2024 7:00am EST Immunocore reports third quarter financial results and provides a business update
Sep 14, 2024 3:00am EDT Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Aug 08, 2024 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Aug 01, 2024 7:00am EDT Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Jun 18, 2024 7:00am EDT Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Jun 01, 2024 8:00am EDT Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
May 31, 2024 4:05pm EDT Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 29, 2024 7:00am EDT Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 08, 2024 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Feb 28, 2024 7:34am EST Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Feb 22, 2024 7:00am EST Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Feb 21, 2024 7:00am EST Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Jan 05, 2024 7:00am EST Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Nov 07, 2023 7:00am EST Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 01, 2023 4:01pm EDT Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
Oct 21, 2023 8:45am EDT Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
Aug 10, 2023 7:00am EDT Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 03, 2023 8:00am EDT Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
Jun 03, 2023 7:00am EDT Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
May 10, 2023 7:00am EDT Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023 4:30pm EDT Immunocore to present at the Bank of America Securities 2023 Health Care Conference
Apr 18, 2023 7:00am EDT Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
Apr 11, 2023 7:00am EDT Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
Feb 23, 2023 7:00am EST Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
Feb 22, 2023 7:00am EST Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Jan 09, 2023 7:00am EST Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
Dec 08, 2022 6:30am EST Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
Dec 02, 2022 7:30am EST Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
Nov 11, 2022 9:00am EST Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
Nov 09, 2022 7:00am EST Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
Sep 09, 2022 10:00am EDT Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
Aug 10, 2022 7:00am EDT Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 03, 2022 7:00am EDT Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
Aug 01, 2022 7:00am EDT Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Jun 25, 2022 4:00am EDT Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
Jun 08, 2022 7:00am EDT The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Jun 06, 2022 7:00am EDT Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 03, 2022 7:00am EDT Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
May 26, 2022 6:00pm EDT Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11, 2022 7:00am EDT Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 04, 2022 7:00am EDT European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Mar 03, 2022 7:00am EST Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
Feb 25, 2022 2:00am EST Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Jan 26, 2022 7:00am EST Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
Dec 06, 2021 7:00am EST Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
Nov 10, 2021 7:00am EST Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 09, 2021 8:01am EST Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Oct 18, 2021 7:30am EDT Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
Sep 22, 2021 6:00pm EDT Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
Sep 20, 2021 7:00am EDT Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial
Sep 13, 2021 4:30pm EDT Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
Sep 08, 2021 7:00am EDT Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Aug 24, 2021 7:00am EDT Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Aug 11, 2021 7:00am EDT Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update